Bio-Rad Laboratories, Inc. (NYSE:BIO) COO Andrew J. Last Sells 3,000 Shares

Bio-Rad Laboratories, Inc. (NYSE:BIO) COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $324.07 on Wednesday. The company has a 50 day moving average price of $315.78 and a 200-day moving average price of $307.56. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $384.37. The company has a market capitalization of $9.24 billion, a PE ratio of -31.28 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.99. The firm had revenue of $638.50 million during the quarter, compared to the consensus estimate of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The company’s revenue was down 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.00 earnings per share. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.31 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $401.00 target price on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. Citigroup boosted their target price on Bio-Rad Laboratories from $300.00 to $350.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price for the company. Jefferies Financial Group restated a “hold” rating and set a $315.00 target price (down previously from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday, June 3rd. Finally, StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Hold” and an average target price of $358.20.

Hedge Funds Weigh In On Bio-Rad Laboratories

A number of large investors have recently bought and sold shares of BIO. Brio Consultants LLC bought a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $840,000. Victory Capital Management Inc. raised its stake in Bio-Rad Laboratories by 48.7% in the fourth quarter. Victory Capital Management Inc. now owns 17,671 shares of the medical research company’s stock worth $5,706,000 after buying an additional 5,790 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Bio-Rad Laboratories by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 214,234 shares of the medical research company’s stock worth $69,174,000 after buying an additional 10,040 shares in the last quarter. Principal Securities Inc. bought a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $41,000. Finally, BNP Paribas Financial Markets raised its stake in Bio-Rad Laboratories by 88.8% in the fourth quarter. BNP Paribas Financial Markets now owns 26,925 shares of the medical research company’s stock worth $8,694,000 after buying an additional 12,662 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.